Cetuximab

1L, first-line; ADCC, antibody-dependent cell-mediated cytotoxicity; ASCO, American Society of Clinical Oncology; CDC, complement-dependent cytotoxicity; CRC, colorectal cancer; ESMO, European Society for Medical Oncology; FDA, Food & Drug Administration; HPV, human papillomavirus-positive; ICD, immunogenic cell death; LA SCCHN, locally advanced squamous cell carcinoma of the head and/or neck; MoA, mechanism of action; mCRC, metastatic colorectal cancer; OPC, oropharyngeal cancer; R/M, recurrent and/or metastatic; SCCHN, squamous cell carcinoma of the head and/or neck; SoC, standard of care; VEGF, vascular endothelial growth factor.

1. Bray F, et al. CA Cancer J Clin 2024;74:229–263;
2. GLOBOCAN. 2022. Available at: https://gco.iarc.fr/today/en/dataviz/mapsheatmap?mode=population&cancers=41 (last accessed April 2025);
3. Cancer Tomorrow. Available at: https://gco.iarc.fr/tomorrow/en/dataviz/tables?types=0&cancers=41&populations=903_904_905_908_909_935_900&years=2050 (last accessed April 2025);
4. Keum N, et al. Nat Rev Gastroenterol Hepatol 2019;16:713–732;
5. Barsouk A, et al. Med Sci (Basel) 2023 Jun 13;11:42;
6. Wild CP, Weiderpass E, Stewart BW, editors (2020). World Cancer Report: Cancer Research for Cancer Prevention. Lyon, France: International Agency for Research on Cancer. Available from: http://
7. Taberna M, et al. Ann Oncol 2017;28:2386–2398;
8. Licitra L, et al. Hematol Oncol Clin N Am 2008;22:1143–1153;
9. Chaturvedi AK, et al. J Clin Oncol 2013;31:4550–4559;
10. Shaikh MH, et al. Cancer Epidemiol 2015;39:923–938;
11. Ang KK, et al. Cancer Res 2002;62:7350–7356;
12. Scaltriti M and Baselga J Clin Cancer Res 2006;12:5268–5272;
13. Herbst RS, et al. Cancer 2002;94:1593–1611;
14. Huang C-W, et al. BMC Cancer 2013;13:599;
15. Zhao B, et al. Oncotarget 2017;8:3980–4000;
16. Koncina E, et al. Cancers (Basel) 2020;12:319;
17. Ross JS, et al. Am J Clin Pathol 2003;119:472–485;
18. Martinelli E, et al. Clin Exp Immunol 2009;158:1–9;
19. Ferris RL, et al. Cancer Treatment Rev 2018;63:48–60;
20. Goldstein NI, et al. Clin Cancer Res 1995;1:1311–1318;
21. Troiani T, et al. ESMO Open 2016;1:e000088;
22. Sato JD, et al. Mol Biol Med 1983;1:511–529;
23. Naramura M, et al. Cancer Immunol Immunother 1993;37:343–349;
24. Merck KGaA Submits Erbitux Head, Neck Cancer Data for Approval. Available at: https://oralcancernews.org/wp/merck-kgaa-submits-erbitux-head-neck-cancer-data-for-approval (last accessed April 2025)
25. Baselga J, et al. J Clin Oncol 2000;18:904–14;
26. Merck KGaA to announce European colorectal cancer study data of Erbitux (Cetuximab) at ASCO. Available at: https://www.pharmaceuticalonline.com/doc/merck-kgaa-to-announce-european-colorectalca-0001 (last accessed April 2025);
27. Kirkpatrick P, et al. Nat Rev Drug Disc 2004;3:549–550;
28. Information on Cetuximab (marketed as Erbitux). Available at: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-cetuximab-marketed-erbitux (last accessed April 2025);
29. Cunningham D, et al. New Engl J Med 2004;351:377–345;
30. European Commission. 2004. European Commission Decision on Erbitux^® - Marketing authorization. EMEA/H/C/558. Available at: https://ec.europa.eu/health/documents/community-register/html/h281.htm (last accessed April 2025);
31. Bonner JA, et al. J Clin Oncol 2004;22(suppl 14):5507;
32. Baselga J, et al. J Clin Oncol 2005;23:5568–5577;
33. Herbst R, et al. J Clin Oncol 2005;23:5578-5587;
34. Bourhis J, et al. J Clin Oncol 2006;24:2866–2872;
35. European Commission. 2006. European Commission Decision on Erbitux^® - Amendment to marketing authorization. EMEA/H/C/558/II/5. Available at: https://ec.europa.eu/health/documents/communityregister/html/h281.htm (last accessed April 2025);
36. Vermorken J, et al. J Clin Oncol 2007;25:2171–7;
37. European Commission. 2008. European Commission Decision on Erbitux^® - Amendment to marketing authorization. EMEA/H/C/558/II/26, 28. Available at: https://ec.europa.eu/health/documents/community-register/html/h281.htm (last accessed April 2025);
38. Pessino A, et al. Ann Oncol 2008;19:711–716;
39. Vermorken J, et al. N Engl J Med 2008;359:1116–1127;
40. European Commission. 2008. European Commission Decision on Erbitux^® - Amendment to marketing authorization. EMEA/H/C/558/II/20. Available at:https://ec.europa.eu/health/documents/communityregister/html/h281.htm (last accessed April 2025);
41. Van Cutsem E, et al. N Engl J Med 2009;360:1408–1417;
42. Bokemeyer C, et al. J Clin Oncol 2009;27:663–671;
43. European Commission. 2011. European Commission Decision on Erbitux^® - Amendment to marketing authorization. EMEA/H/C/558/II/42. Available at: https://ec.europa.eu/health/documents/communityregister/html/h281.htm (last accessed April 2025);
44. European Commission. 2012. European Commission Decision on Erbitux^® - Amendment to marketing authorization. EMEA/H/C/558/II/47. Available at: https://ec.europa.eu/health/documents/communityregister/html/h281.htm (last accessed April 2025);
45. Bokemeyer C, et al. Eur J Cancer 2015;10:1466–1475;
46. Santini D, et al. Ann Oncol 2012;23:2313–2318;
47. Schmoll HJ, et al. Ann Oncol 2012;23:2479–2516;
48. European Commission. 2013. European Commission Decision on Erbitux^® - Amendment to marketing authorization. EMEA/H/C/558/II/62. Available at: https://ec.europa.eu/health/documents/communityregister/html/h281.htm (last accessed April 2025);
49. Clark JI, et al. Med Oncol 2013;30:358;
50. Yoshino T, et al. Jpn J Clin Oncol 2013;43:524–531;
51. ASCO 2013: Cetuximab superior to bevacizumab for advanced colorectal cancer. Available at: https://ecancer.org/en/news/4116-asco-2013-cetuximab-superior-to-bevacizumab-for-advanced-colorectalcancer (last accessed April 2025);
52. Exclusion of patients with RAS mutations identifies a population which is more likely to benefit from cetuximab. Available at: https://www.esmo.org/meeting-calendar/past-meetings/european-cancercongress-2013/News/expended-mutational-analysis-of-phase-iii-fire-3-trial-data-shows-most-patients-with-wild-type-ras-metastatic-colorectal-cancer-benefit-from-first-line-folfiri-plus-cetuximabtreatment (last accessed April 2025);
53. Hildebrandt B, et al. Recent Results Cancer Res 2007;176:135–143
54. Venook AP, et al. J Clin Oncol 2014;32 (suppl 18):LBA3;
55. Heinemann V, et al. Lancet Oncol 2014;15:1065–1075;
56. Guo Y, et al. Head Neck 2015;37:1081–1087;
57. Bokemeyer C, et al. Eur J Cancer 2015;51:1243–1252;
58. Van Cutsem E, et al. J Clin Oncol 2015;33:692–700;
59. Stintzing S, et al. Lancet Oncol 2016;17:1426–1434;
60. Tejpar S, et al. JAMA Oncol 2017;3:194–201;
61. Venook AP, et al. J Clin Oncol 2017;35 (suppl 15):3503;
62. Bossi P, et al. Ann Oncol 2017;28:2820–2826;
63. Tahara M, et al. Ann Oncol 2018;29:1004–1009
64. Osawa H, et al. Ann Oncol 2018;29(suppl 8);
65. Aranda E, et al. Eur J Cancer 2018;101:263–272;
66. Qin S, et al. J Clin Oncol 2018;36:3031–3039;
67. Guigay J, et al. J Clin Oncol 2019;37(suppl 15):6002;
68. Klinghammer K, et al. Eur J Cancer 2019;122:53–60;
69. Cremolini C, et al. JAMA Oncol 2019;5:343–350;
70. Burtness B, et al. Lancet 2019;394:1915–1928;
71. Lenz H-J, et al. J Clin Oncol 2019;37:1876–1885;
72. Wang Z-X, et al. J Natl Compr Canc Netw 2019;17:805–811;
73. Kopetz S, et al. J Clin Oncol 2020;38 (suppl 15):4001;
74. Masuishi T, et al. Br J Cancer 2020;123:1490–1495;
75. Folprecht G, et al. J Clin Oncol 2020;38 (suppl 15):4024
76. Guigay J, et al. Lancet Oncol. 2021;22:463–475;
77. Guo Y, et al. Eur J Cancer 2021;156:35–45;
78. Heinemann V, et al. BR J Cancer 2021;124:587–594;
79. Klinghammer K, et al. ESMO Open 2021;6:100242;
80. Pinto C, et al. Ann Oncol 2022;33(suppl 7):S808–S869 – LBA22;
81. Chibaudel B, et al. J Clin Oncol 2022;40 (suppl 16):3504;
82. Psyrri A, et al. Ann Oncol 2023;34:262–274;
83. Orlandi A, et al. ASCO 2023 (Abstract No. 3603 – poster);
84. Qin S, et al. Future Oncol 2023;19:1053–1061;
85. Haddad RI, et al. J Clin Oncol 2023;41:2166–2180;
86. Sunakawa Y, et al. Ann Oncol 2023;34(suppl 2):S410–457;
87. Kopetz S, et al. J Clin Oncol 2023;41:TPS3627–TPS3627;
88. ESMO clinical practice guidelines 2025. Available at: https://www.esmo.org/guidelines/guidelines-by-topic (last accessed April 2025);
89. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) 2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed [April 2025]. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.